Cancer clinical trials in the region Nouvelle-Aquitaine
397 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Lung cancer
#NCT06170788
#2023-503376-24-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Lung cancer
#NCT06561386
#2024-513682-40-01
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
NTRK-1/2/3
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
BRAF
EGFR
ROS-1
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
10 recruiting sites
Bristol-Myers Squibb
Phase 3
Lung cancer
#NCT05211895
#2023-506891-28-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Chemotherapy
Radiotherapy
Excluded genetic anomalies
ALK
EGFR
11 recruiting sites
AstraZeneca
Phase 3
Colon cancer
Rectal cancer
#NCT05253651
#2024-514180-25-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
KRAS G12C
KRAS non G12C
NRAS
18 recruiting sites
Seagen
Phase 3
Colon cancer
Rectal cancer
#NCT06750094
#2024-513853-66-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded genetic anomalies
BRAF
HER2
KRAS G12C
KRAS non G12C
MSI/dMMR
NRAS
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
3 recruiting sites
Janssen
Phase 3
Colon cancer
Rectal cancer
#NCT04188145
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Chemotherapy
12 recruiting sites
CHU Dijon
Phase 3
Lung cancer
#NCT04339218
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Institut Bergonié
Phase 3
Breast cancer
#NCT05078047
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Locally Advanced
Metastatic
Required previous treatments at advanced or metastatic stage
Immunotherapy
25 recruiting sites
UNICANCER
Phase 3
Colon cancer
Rectal cancer
#NCT05078047
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
MSI/dMMR
Required previous treatments at advanced or metastatic stage
Immunotherapy
25 recruiting sites
UNICANCER
Phase 3
Breast cancer
#NCT06312176
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Chemotherapy
8 recruiting sites
Merck Sharp & Dohme LLC